1 Cammà C, "Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials" 224 : 47-54, 2002
2 Yi-Sheng Liu, "Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma" 대한영상의학회 16 (16): 125-132, 2015
3 Tu J, "The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma" 95 : e5606-, 2016
4 Llovet JM, "The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma" 10 (10): S115-S120, 2004
5 Angelico M, "TACE vs DEB-TACE: Who wins?" 48 : 796-797, 2016
6 Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival" 37 : 429-442, 2003
7 Xie ZB, "Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma" 45 : 190-200, 2015
8 Duan F, "Superselective chemoembolization of HCC: comparison of short-term safety and efficacy between drug-eluting LC beads, quadraSpheres, and conventional ethiodized oil emulsion" 278 : 612-621, 2016
9 Riaz A, "Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologicpathologic correlation" 54 : 695-704, 2011
10 Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma" 35 : 1164-1171, 2002
1 Cammà C, "Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials" 224 : 47-54, 2002
2 Yi-Sheng Liu, "Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma" 대한영상의학회 16 (16): 125-132, 2015
3 Tu J, "The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma" 95 : e5606-, 2016
4 Llovet JM, "The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma" 10 (10): S115-S120, 2004
5 Angelico M, "TACE vs DEB-TACE: Who wins?" 48 : 796-797, 2016
6 Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival" 37 : 429-442, 2003
7 Xie ZB, "Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma" 45 : 190-200, 2015
8 Duan F, "Superselective chemoembolization of HCC: comparison of short-term safety and efficacy between drug-eluting LC beads, quadraSpheres, and conventional ethiodized oil emulsion" 278 : 612-621, 2016
9 Riaz A, "Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologicpathologic correlation" 54 : 695-704, 2011
10 Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma" 35 : 1164-1171, 2002
11 Riaz A, "Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90microspheres" 49 : 1185-1193, 2009
12 Lammer J, "Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study" 33 : 41-52, 2010
13 Bruix J, "Prognostic prediction and treatment strategy in hepatocellular carcinoma" 35 : 519-524, 2002
14 Llovet JM, "Prognosis of hepatocellular carcinoma: the BCLC staging classification" 19 : 329-338, 1999
15 Hong K, "New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer" 12 : 2563-2567, 2006
16 Lencioni R, "Modified RECIST (mRECIST) assessment for hepatocellular carcinoma" 30 : 52-60, 2010
17 Lee M, "Korean multicenter registry of transcatheter arterial chemoembolization with drug-eluting embolic agents for nodular hepatocellular carcinomas:six-month outcome analysis" 28 : 502-512, 2017
18 Forner A, "Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?" 115 : 616-623, 2009
19 Zou JH, "Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a metaanalysis" 17 : 510-517, 2016
20 Facciorusso A, "Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis" 48 : 571-577, 2016
21 Lee KH, "Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer" 33 : 576-582, 2010
22 Huang K, "Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma" 29 : 920-925, 2014
23 Cucchetti A, "Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma" 48 : 798-805, 2016
24 Lee YK, "Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size" 32 : 487-496, 2017
25 Bruix J, "Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver" 35 : 421-430, 2001
26 Varela M, "Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics" 46 : 474-481, 2007
27 Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial" 359 : 1734-1739, 2002